Novo Nordisk has launched a pioneering subscription program for its Wegovy obesity treatment, offering cash-paying patients a way to secure lower, predictable monthly prices. Patients can select from three, six, or twelve-month plans for either the Wegovy injection or its newly introduced oral form, with potential savings of up to $1,200 annually on the injection and $600 on the pill. This initiative aims to enhance patient adherence by providing a consistent pricing structure, addressing long-standing issues related to treatment discontinuation.
The subscription model arrives as Novo faces increasing competition from Eli Lilly, which currently dominates the GLP-1 market with a 60% share. The Wegovy pill has gained traction since its U.S. launch in January, primarily attracting new patients who had not previously used GLP-1 injections. With the subscription program, Novo seeks to solidify its market position and capture as many patients as possible before Lilly’s competing oral GLP-1 is released.
For market professionals, this subscription model could signify a shift in how pharmaceutical companies approach patient access and adherence, potentially influencing pricing strategies across the sector.
Source: cnbc.com